Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#triple> ?p ?o ?g. }
- triple label "dexamethasone increased mortality" assertion.
- triple label "only dexamethasone and remdesivir shown To date" assertion.
- triple label "only dexamethasone and remdesivir be effective" assertion.
- triple label "multiple alternate dosing of NEPA ( netupitant / palonosetron ) without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting , with a good tolerability profile" assertion.
- triple label "The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine" assertion.
- triple label "dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine" assertion.
- triple label "dexamethasone have a better result in hospitalized patients , especially in low - resources settings" assertion.
- triple label "dexamethasone ( Dex ) bind to both the viral and host receptors as a potential drug candidate for COVID-19" assertion.
- triple label "dexamethasone ( Dex ) could bind to both the viral and host receptors as a potential drug candidate for COVID-19" assertion.
- triple label "several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir used because of several existing licensed drugs such as chloroquine , hydroxychloroquine , methylprednisolone , dexamethasone , and remdesivir s potential efficacy in inhibiting COVID-19" assertion.
- triple label "Thirty - three patients ( 21.9 % ) in the dexamethasone group vs 43 ( 29.1 % ) in the standard care group experienced secondary infections" assertion.
- triple label "intravenous dexamethasone increases the number of ventilator - free days among patients with COVID-19 - associated ARDS" assertion.
- triple label "use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator - free days ( days alive and free of mechanical ventilation ) over the first 28 days" assertion.
- triple label "use of intravenous dexamethasone plus standard care compared with standard care alone" assertion.
- triple label "A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management" assertion.
- triple label "A regimen of hydroxychloroquine , azithromycin , and dexamethasone initiated in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management" assertion.
- triple label "Although the anti - inflammatory corticosteroid dexamethasone 's administration for viral infection managing is controversial is increasing evidence demonstrating that the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone treatment diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome ( ARDS ) that required invasive mechanical ventilation" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone being deleterious for diabetics and hypertensive patients , two major COVID-19 risk groups" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone inducing hyperglycemia and sodium retention" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone impairing viral clearance" assertion.
- triple label "the anti - inflammatory corticosteroid dexamethasone taking into consideration underlying medical conditions and COVID-19 disease severity" assertion.
- triple label "dexamethasone be effective in patients in need of respiratory assistance" assertion.
- triple label "visual acuity outcomes to topical prednisolone acetate the dexamethasone intracanalicular insert is an appropriate means of postoperative symptom control in this quality of life - conscious population" assertion.
- triple label "the dexamethasone intracanalicular insert produced comparable ocular comfort , corneal staining" assertion.
- triple label "Low - dose dexamethasone therapy is the best therapeutic approach" assertion.
- triple label "Remdesivir , dexamethasone , azithromycin , favipiravir , lopinavir / ritonavir , atazanavir , hydroxychloroquine , interferon beta , ribavirin , tocilizumab , anakinra and sarilumab identified as experimental drugs being used in the associated coronavirus disease 2019 ( COVID)-19 ) trials as of November 2020" assertion.
- triple label "dexamethasone or other corticosteroids and IL-6 inhibitors including sarilumab , tocilizumab , and siltuximab" assertion.
- triple label "either methylprednisolone or dexamethasone associated with increased survival in COVID-19 patients at risk of hyper - inflammatory response" assertion.
- triple label "high dose corticosteroid pulse therapy ( HDCPT ) with either methylprednisolone or dexamethasone be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper - inflammatory response" assertion.
- triple label "etoposide and dexamethasone A follow - up CT chest revealed evolution of the honeycombing lesions" assertion.
- triple label "low - dose dexamethasone be in moderate to severe cases and trials with anti - interleukin agents ( e.g. , tocilizumab , anakinra , siltuximab ) and non - steroidal anti - inflammatory drugs" assertion.
- triple label "low - dose dexamethasone appears To target the inflammatory cascade" assertion.
- triple label "The antiviral agent , remdesivir , and the immunomodulator , dexamethasone , and inpatients who require mechanical ventilation receive the immunomodulator , dexamethasone monotherapy" assertion.
- triple label "Favipiravir , ciclesonide , dexamethasone , and heparin administered in 106 , 168 , 65 , and 38 patients , respectively , but not remdesivir" assertion.
- triple label "heparin and dexamethasone showed improvement" assertion.
- triple label "dexamethasone - related complications result from using higher doses of dexamethasone" assertion.
- triple label "early administration of dexamethasone in combination with immunoglobulin ( IV)-IG ) and interferon - beta reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19" assertion.
- triple label "the administration of dexamethasone started In Intervention Group 2, will, "within the first 24 hours time of admission"" assertion.
- triple label "the administration of dexamethasone continued In Intervention Group 2, will, for 48 - 72 hours" assertion.
- triple label "Single - day dexamethasone dosing recommended over multi - day dosing for regimens with high emetogenic risk excluding high - dose cisplatin , preferably in combination with palonosetron , netupitant , and olanzapine" assertion.
- triple label "dexamethasone exposure minimize while maintaining control of nausea and emesis" assertion.
- triple label "administration of adjunctive dexamethasone with the antibiotics lessens neurologic sequelae" assertion.
- triple label "LABAs and dexamethasone exert synergistic effects that will augment both anti - inflammatory and fibronectin - mediated anticoagulant effects" assertion.
- triple label "dexamethasone combining with fast long - acting beta-2 adrenergic agonists ( LABAs ) , such as formoterol and salmeterol" assertion.
- triple label "dexamethasone demonstrate any protective advantage" assertion.
- triple label "dexamethasone therapy initiated On day 6" assertion.
- triple label "adjunctive treatment of established ARDS caused by the coronavirus disease 2019 ( COVID)-19 ) with intravenous dexamethasone change the pulmonary and systemic inflammatory response" assertion.
- triple label "adjunctive treatment of established ARDS caused by the coronavirus disease 2019 ( COVID)-19 ) with intravenous dexamethasone reduce morbidity" assertion.
- triple label "a number of corticosteroids , including and especially methylprednisolone and dexamethasone demonstrated remarkable efficacyparticularly for COVID-19 patients who underwent mechanical ventilation" assertion.
- triple label "the efficacy and safety of treatment with dexamethasone in patients evaluate with BACKGROUND Spontaneous intracerebral hemorrhage ( ICH )" assertion.
- triple label "CONCLUSION Clear evidence of a beneficial or negative effect of dexamethasone is lacking" assertion.
- triple label "the addition of dexamethasone to local infiltration of analgesia ( LIA ) prolong the duration of analgesic effects" assertion.
- triple label "the addition of dexamethasone to local infiltration of analgesia ( LIA ) provide significant analgesic effects" assertion.
- triple label "pre - emptive scalp infiltration with a steroid ( dexamethasone ) plus a local anesthetic ( ropivacaine ) achieve superior postoperative analgesic effects to a local anesthetic ( ropivacaine ) alone in adult patients undergoing a craniotomy" assertion.
- triple label "dexamethasone or methylprednisolone Further research needed to understand the pathogenesis , resemblance and differences of this syndrome with a severe Kawasaki disease ( KD ) , understanding of heart injuiry and early recognition for the need of urgent care" assertion.
- triple label "dexamethasone or methylprednisolone Further understand the pathogenesis , resemblance and differences of this syndrome with a severe Kawasaki disease ( KD ) , understanding of heart injuiry and early recognition for the need of urgent care" assertion.
- triple label "dexamethasone improves outcomes in patients on mechanical ventilators or on oxygen" assertion.
- triple label "mg/2 ml dexamethasone 21 - phosphate administered near operated sites" assertion.
- triple label "low - dose dexamethasone used Therefore, may, in obese children" assertion.
- triple label "mortality benefits with dexamethasone seen in patients, with, coronavirus disease" assertion.
- triple label "dexamethasone levels were detectable" assertion.
- triple label "Administration of dexamethasone to mitigate postoperative nausea and vomiting suggested to improve, after pancreatic ductal adenocarcinoma ( PDAC ) resection" assertion.
- triple label "Administration of dexamethasone mitigate postoperative nausea and vomiting" assertion.
- triple label "Intraoperative dexamethasone associated with differences in postoperative major complications ( PMCs ) ( 21.1 vs 19.3 % ; p = 0.68 ) , postoperative pancreatic fistulas ( 6.3 vs 6.7 % ; p = 0.88 ) , or composite infectious complications ( 28.7 vs 24.7 % ; p = 0.39 )" assertion.
- triple label "dexamethasone associated with any improvement in median recurrence - free survival ( RFS ) ( 17 vs 17 months ; p = 0.99 ) or overall survival ( OS ) ( 46 vs 43 months ; p = 0.90 )" assertion.
- triple label "dexamethasone failed to demonstrate any protective advantage in terms of mitigating short - term PMCs or infectious complications , or to confer any long - term survival benefit" assertion.
- triple label "dexamethasone mitigating short - term PMCs or infectious complications" assertion.
- triple label "dexamethasone confer any long - term survival benefit" assertion.
- triple label "administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19" assertion.
- triple label "dexamethasone 20 mg intravenously followed by dexamethasone 10 mg intravenously once daily on day 6 - 10" assertion.
- triple label "the dexamethasone was top - ranked in the prediction , which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support" assertion.
- triple label "the dexamethasone ranked in the prediction , which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support" assertion.
- triple label "only two treatments , remdesivir and dexamethasone demonstrated clinical efficacythrough randomized controlled trials ( RCTs ) in seriously ill patients" assertion.
- triple label "early use of INTERVENTION Use of intravenous remdesivir and dexamethasone be beneficial in refractory Myasthenia gravis ( MG ) cases even with chronic immunosuppression and severe COVID-19 infection" assertion.
- triple label "dexamethasone suppressed exogenous BID expression and the antitumor effect of a promoter system ( TTS ) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo" assertion.
- triple label "dexamethasone ( DEX ) treatment improve the mortality ( 17 out of 20 versus 16 out of 20 deaths in the DEX - treated infected group DEX - treated versus The infected group )" assertion.
- triple label "dexamethasone ( DEX ) treatment alleviate clinical signs , including weight loss , decreased food intake and inactivity" assertion.
- triple label "dexamethasone treatment ( 2.5 mg.kg(-1 ) ) from days 3 - 14 post inoculation has no beneficial effect on acute respiratory distress syndrome( ARDS ) induced by the H5N1 viral infection in mice" assertion.
- triple label "dexamethasone ) showed "anti - allergic drugs ( olopatadine , ketotifen ) , antibiotics ( clarithromycin ) and corticosteroids ( hydrocortisone , dexamethasone ) s potency as highly effective mast cell stabilizers"" assertion.
- triple label "dexamethasone ) inhibited the process of exocytosis" assertion.
- triple label "p & lt;0 05 ) NNT of dexamethasone vs usual care was 17 3 ( 95%CI 14 9–20 6 ) in subjects & lt;70 years" assertion.
- triple label "dexamethasone is in male subjects & lt;70 years" assertion.
- triple label "azithromycin , dexamethasone , tocilizumab , sarilumab , famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management" assertion.
- triple label "Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs 's off - label use against COVID-19 , such as anti - retroviral drugs ( remdesivir , favipiravir , and lopinavir - ritonavir combination ) , biologics ( tocilizumab ) , antibiotics ( azithromycin ) , antiparasitics ( chloroquine and hydroxychloroquine ) , and corticosteroids ( dexamethasone ) remains the associated clinical neuropsychiatric adverse events" assertion.
- triple label "dexamethasone and COVID-19 antibody transfusion called convalescent plasma therapy s use" assertion.
- triple label "Use of non - steroidal anti - inflammatories , dexamethasone and prophylactic antibiotics associated with smaller reductions in LOS" assertion.
- triple label "Treatment with the recombinant interleukin-1 ( IL)-1 ) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement , reduction in serum inflammatory markers and a marked recovery in CMR - based markers of inflammation and contractile dysfunction" assertion.
- triple label "dexamethasone added to cover the possibility of COVID-19" assertion.
- triple label "positive data with dexamethasone contributed to an increasing proportion of patients who are surviving without the need for mechanical ventilation" assertion.
- triple label "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone considered for COVID-19 therapy" assertion.
- triple label "Only dexamethasone shown reduce mortality in severe cases, further supporting a role for inflammation in disease severity" assertion.
- triple label "Only dexamethasone supporting a role for inflammation in disease severity" assertion.
- triple label "Only dexamethasone reduce mortality in severe cases" assertion.
- triple label "oral or intravenous low - dose dexamethasone using in adults with COVID-19 disease who require oxygen or mechanical ventilation" assertion.
- triple label "dexamethasone , a widely available and inexpensive corticosteroid with anti - inflammatory effects , shown a great promise in reducing mortality rates in COVID-19 patients" assertion.
- triple label "linoleate and dexamethasone stabilize the locked spike conformation" assertion.
- triple label "linoleate and dexamethasone reducing the opportunity for ACE2 interaction" assertion.
- triple label "The MerTK - dependent anti - inflammatory mechanisms of dexamethasone , and the homeostatic function of TAM pathways that maintain RA in remission advocate the therapeutic MerTK agonism to ameliorate the cytokine storm and pneumonitis of severe COVID-19" assertion.